BlackRock Advisors’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

BlackRock Advisors’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$719K	Buy	69,847 +189	+0.3%	+$1.73K	﹤0.01%	2015
2016 Q3	$704K	Sell	69,658 -1,674	-2%	-$18.3K	﹤0.01%	1997
2016 Q2	$801K	Buy	71,332 +1,509	+2%	+$19.2K	﹤0.01%	1867
2016 Q1	$954K	Sell	69,823 -374	-0.5%	-$5.38K	﹤0.01%	1763
2015 Q4	$1.33M	Sell	70,197 -12,811	-15%	-$278K	﹤0.01%	1587
2015 Q3	$1.56M	Buy	83,008 +28,181	+51%	+$479K	﹤0.01%	1447
2015 Q2	$816K	Sell	54,827 -77,216	-58%	-$1.18M	﹤0.01%	1816
2015 Q1	$2M	Sell	132,043 -108,606	-45%	-$1.52M	﹤0.01%	1228
2014 Q4	$3.21M	Buy	240,649 +34,385	+17%	+$444K	﹤0.01%	1072
2014 Q3	$2.6M	Sell	206,264 -72,653	-26%	-$705K	﹤0.01%	1108
2014 Q2	$2.82M	Buy	278,917 +45,815	+20%	+$442K	﹤0.01%	1087
2014 Q1	$3.13M	Buy	+233,102	New	+$3.29M	﹤0.01%	1070

Other funds holding CNCE

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

SAM

Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return

BlackRock Advisors's CNCE Position: Q4 2016 in Review

BlackRock Advisors increased its Concert Pharmaceuticals, Inc. (CNCE) stake by 0.27% in Q4 2016, buying an estimated $1.73K and bringing the position to 69,847 shares worth $719K. The position accounts for ﹤0.01% of the portfolio, ranked #2015.

BlackRock Advisors first reported a position in CNCE in Q1 2014 and has held it in 12 quarters since. The position peaked at $3.21M in Q4 2014. 89 funds tracked by Wall St. Rank hold CNCE as of Q4 2016.

BlackRock Advisors held 69,847 shares of Concert Pharmaceuticals, Inc. worth $719K as of Q4 2016.
BlackRock Advisors bought 189 Concert Pharmaceuticals, Inc. shares in Q4 2016, an estimated $1.73K.
Concert Pharmaceuticals, Inc. made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #2015 holding.
BlackRock Advisors first reported a position in Concert Pharmaceuticals, Inc. in Q1 2014 and has held it in 12 quarters since.
BlackRock Advisors's Concert Pharmaceuticals, Inc. position peaked at $3.21M in Q4 2014.
89 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.